Bayer AG
German multinational conglomerate headquartered in Leverkusen, operating across pharmaceuticals, consumer healthcare, agricultural chemicals, seeds, and biotechnology; ranks among the world's largest biomedical companies by revenue.
相关临床试验
2557
839 进行中
药物批准
330
批准总数
监管机构
6
监管机构数
成立时间
1863
尚未招募
16
0.6%
No Longer Available
8
0.3%
终止
98
3.8%
招募中
51
2.0%
暂停
1
0.0%
Approved For Marketing
1
0.0%
撤回
34
1.3%
进行中（未招募）
823
32.2%
已完成
1524
59.6%
- The FDA granted accelerated approval to Bayer's oral tyrosine kinase inhibitor HYRNUO (sevabertinib) for treatment-naive adults with locally advanced or metastatic nonsquamous NSCLC harboring HER2 TKD activating mutations. - Approval was based on SOHO-01 Cohort F data showing a 75% objective response rate (95% CI: 64%-85%) in 69 treatment-naive patients, with 73% of responders maintaining response at six months. - The indication expands sevabertinib's existing November 2025 accelerated approval, which covered patients with HER2 TKD activating mutations who had received prior systemic therapy. - Continued approval may depend on confirmatory benefit in the ongoing Phase III SOHO-02 trial comparing sevabertinib with standard of care in treatment-naive advanced HER2-mutated NSCLC.
- EpilepsyGTx and CDMO Viralgen have partnered to manufacture EPY201, an investigational AAV gene therapy for focal refractory epilepsy, ahead of first-in-human clinical trials. - Viralgen will deploy its proprietary Aava platform, which enables high-yield, scalable AAV manufacturing across serotypes and has supported production of 1,500 AAV batches. - EPY201 (AAV9-CAMK2A-EKC) is delivered directly into the seizure focus via intraparenchymal administration to reduce local neuronal hyperexcitability while limiting exposure beyond the target region. - Focal refractory epilepsy affects roughly 10 million patients worldwide, including two million across the US, UK and EU, and the first-in-human trial is expected to begin in the first half of 2027.
- AskBio presented baseline characteristics from the Phase 2 GenePHIT trial of the investigational gene therapy umiposgene parvec (AB-1002) at the European Society of Cardiology Congress in Munich, Germany. - GenePHIT randomized more than 170 participants across 64 sites in 12 countries, making it one of the largest gene therapy trials conducted in heart failure to date. - The enrolled population reflects a representative non-ischemic heart failure with reduced ejection fraction (HFrEF) cohort receiving guideline-directed medical therapy. - Initial efficacy and safety outcomes from GenePHIT are expected in the first half of 2027.
- The radioligand therapy market was valued at USD 2.98 billion in 2025 and is forecast to reach USD 15.85 billion by 2035, an 18.2% CAGR. - Novartis received expanded FDA approval in 2026 for Pluvicto in earlier-line metastatic castration-resistant prostate cancer, moving PSMA therapy ahead of chemotherapy. - Eli Lilly advanced 177Lu-PNT2002 into a pivotal Phase 3 trial in biochemically recurrent prostate cancer, while Convergent Therapeutics began Phase III testing of CONV01-alpha. - Alpha-emitter pipeline agents using actinium-225 and lead-212 are the fastest-growing product segment, projected at a 24.6% CAGR through 2035.
- Bayer reported Q2 2026 net sales of EUR 10.9 billion, up 2% year-over-year, with first-half sales reaching EUR 24.3 billion, up 3%. - Pharma sales were broadly flat, but Nubeqa and Kerendia together grew 66%, offsetting a sharp 27% decline in Eylea driven by biosimilar competition. - The anticoagulant asundexian received priority review in the U.S. and China, with launches targeted around end-2026 or early-2027. - First-half free cash flow was negative EUR 2.7 billion, weighed by roughly EUR 2.5 billion in litigation payouts, while a favorable U.S. Supreme Court ruling strengthened Bayer's litigation containment strategy.
- The late-stage chronic kidney disease therapeutics market, valued at $13.02 billion in 2025, is forecast to grow at a 9.88% CAGR to reach $25.20 billion by 2032. - The treatment landscape is shifting from isolated renal care toward integrated cardio-renal-metabolic strategies, with SGLT2 inhibitors and RAAS inhibition serving as established standards alongside emerging biologics and digital adherence solutions. - Dialysis organizations, hospitals, and value-based kidney care programs are increasingly shaping formulary adoption based on operational fit and economic viability rather than clinical data alone. - Key players including AstraZeneca, Novartis, Bayer, Amgen, and Johnson & Johnson are navigating a market where combination logic, treatment sequencing, and real-world evidence are becoming as critical as individual agent efficacy.
- Voyageur Pharmaceuticals has engaged Fluor Corporation to conduct dual feasibility studies for an iodine extraction facility in Oklahoma and an integrated contrast drug manufacturing plant. - The iodine project, developed in collaboration with Bayer AG, will use Voyageur's patent-pending Mueller process to extract high-purity iodine from oilfield brine. - Voyageur has budgeted US$2,350,000 for the Bayer-linked feasibility study, with both studies expected to complete in early 2027, enabling a potential construction decision that year. - The initiative aims to establish North America's first fully integrated "Earth-to-Bottle" contrast media platform, combining domestically sourced barium and iodine to reduce supply chain risks.
- Pediatric oncology possesses exceptional scientific expertise, clinicians, research networks, and pharmaceutical capabilities, but these components are not always connected where they could most influence drug development. - Development-readiness assessment, industry expertise, and targeted funding must enter the process much earlier, before years of academic research have already shaped a program's direction. - The goal should shift from generating more data to generating evidence that can materially change the next development decision, with lessons flowing back into translational research and future programs. - The challenge is not simply more promising science, but creating a development pathway where pediatric oncology research encounters the right expertise and resources early enough to make a difference.
- Viralgen, a leading AAV gene therapy CDMO, has partnered with Elaaj Bio to advance ELJ-101, an investigational gene therapy targeting CDKL5 Deficiency Disorder, a rare pediatric neurological condition. - The collaboration leverages Viralgen's AAV manufacturing expertise to support process development, scale-up manufacturing, and analytical characterization for the preclinical-stage program. - CDKL5 Deficiency Disorder is a severe developmental and epileptic encephalopathy characterized by early-onset seizures and significant neurodevelopmental impairment caused by CDKL5 gene alterations. - The teams plan to initiate the first clinical trial for ELJ-101 in early 2027, with current efforts focused on scaling manufacturing processes to support clinical development.
- AskBio has introduced its commercial manufacturing process to supply ametefgene parvec (AB-1005) for the REGENERATE-PD Phase II trial following FDA IND amendment approval. - The investigational gene therapy delivers GDNF protein to the brain via adeno-associated viral vector to potentially slow Parkinson's disease progression and improve motor outcomes. - REGENERATE-PD is enrolling 127 participants aged 45-75 with moderate-stage Parkinson's disease across sites in Germany, Poland, the United Kingdom, and the United States. - The therapy has received multiple regulatory designations including FDA Fast Track, RMAT designation, and Japan's SAKIGAKE status for Parkinson's disease treatment.
